A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection

Background This study was conducted to investigate whether a panel of eight genetic polymorphisms can predict the prognosis of patients with early stage non-small cell lung cancer (NSCLC) after surgical resection. Materials and Methods We selected eight single nucleotide polymorphisms (SNPs) which have been associated with the prognosis of lung cancer patients after surgery in our previous studies. A total of 814 patients with early stage NSCLC who underwent curative surgical resection were enrolled. The association of the eight SNPs with overall survival (OS) and disease-free survival (DFS) was analyzed. Results The eight SNPs (CD3EAP rs967591, TNFRSF10B rs1047266, AKT1 rs3803300, C3 rs2287845, HOMER2 rs1256428, GNB2L1 rs3756585, ADAMTSL3 rs11259927, and CD3D rs3181259) were significantly associated with OS and/or DFS. Combining those eight SNPs, we designed a prognostic index to predict the prognosis of patients. According to relative risk of death, a score value was assigned to each genotype of the SNPs. A worse prognosis corresponded to a higher score value, and the sum of score values of eight SNPs defined the prognostic index of a patient. When we categorized the patients into two groups based on the prognostic index, high risk group was significantly associated with worse OS and DFS compared to low risk group (aHR for OS = 2.21, 95% CI = 1.69–2.88, P = 8.0 x 10−9, and aHR for DFS = 1.58, 95% CI = 1.29–1.94, P = 1.0 x 10−5). Conclusions Prognostic index using eight genetic polymorphisms may be useful for the prognostication of patients with surgically resected NSCLC.

[1]  J. Park,et al.  RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer , 2015, OncoTarget.

[2]  F. di Costanzo,et al.  Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. , 2013, Lung cancer.

[3]  S. Ramakrishna,et al.  Immune system: a double-edged sword in cancer , 2013, Inflammation Research.

[4]  J. Park,et al.  A Functional Variant at 19q13.3, rs967591G>A, Is Associated with Shorter Survival of Early-Stage Lung Cancer , 2013, Clinical Cancer Research.

[5]  J. Park,et al.  Association between Genetic Variants in Pre-MicroRNAs and Survival of Early-Stage NSCLC , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Dong Sun Kim,et al.  AKT1 polymorphisms and survival of early stage non‐small cell lung cancer , 2012, Journal of surgical oncology.

[7]  Xifeng Wu,et al.  Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients , 2012, Clinical Cancer Research.

[8]  P. Kiely,et al.  RACK1, A multifaceted scaffolding protein: Structure and function , 2011, Cell Communication and Signaling.

[9]  M. Kolev,et al.  Complement in Cancer and Cancer Immunotherapy , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[10]  V. Pankratz,et al.  Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Qing-quan Li,et al.  RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway , 2011, Breast Cancer Research and Treatment.

[12]  J. Park,et al.  Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non‐small‐cell lung cancer , 2010, Cancer science.

[13]  M. Sughrue,et al.  Cancer and the Complement Cascade , 2010, Molecular Cancer Research.

[14]  Toshihide Matsumoto,et al.  Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. , 2010, Lung cancer.

[15]  H. Jeon,et al.  Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.

[16]  Wen-juan Wang,et al.  RACK1: A superior independent predictor for poor clinical outcome in breast cancer , 2009, International journal of cancer.

[17]  Dong Sun Kim,et al.  Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Apte.  A Disintegrin-like and Metalloprotease (Reprolysin-type) with Thrombospondin Type 1 Motif (ADAMTS) Superfamily: Functions and Mechanisms* , 2009, The Journal of Biological Chemistry.

[19]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[20]  H. Popper,et al.  Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. , 2009, Lung cancer.

[21]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.

[22]  G. Casey,et al.  ADAMTSL3/punctin‐2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer , 2007, International journal of cancer.

[23]  J. Yokota,et al.  HOMER2 binds MYO18B and enhances its activity to suppress anchorage independent growth. , 2007, Biochemical and biophysical research communications.

[24]  L. Miller,et al.  RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints , 2007, Oncogene.

[25]  Y. Okada,et al.  ADAMs in cancer cell proliferation and progression , 2007, Cancer science.

[26]  G. Screaton,et al.  Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. , 2006, Human pathology.

[27]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[28]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[29]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[30]  K. O'Byrne,et al.  Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[31]  D. Lawrence,et al.  Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival , 2004, Cancer Research.

[32]  Masahiko Shiraishi,et al.  Correlation between histone acetylation and expression of the MYO18B gene in human lung cancer cells , 2004, Genes, chromosomes & cancer.

[33]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[34]  A. Simon,et al.  Effect of CD3δ Deficiency on Maturation of α/β and γ/δ T-Cell Lineages in Severe Combined Immunodeficiency , 2003 .

[35]  Alfonso Bellacosa,et al.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.

[36]  A. Huttenlocher,et al.  RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. , 2003, Molecular biology of the cell.

[37]  J. Minna,et al.  MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[39]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[40]  B. Hengerer,et al.  RACK1 IS UP‐REGULATED IN ANGIOGENESIS AND HUMAN CARCINOMAS , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[42]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[43]  J. B. Rattner,et al.  ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes , 1997, Chromosoma.

[44]  J. Gmiński,et al.  Anti-elastin antibodies in patients with lung cancer. , 1992, Immunology letters.

[45]  K. Nishioka,et al.  THE COMPLEMENT SYSTEM IN TUMOR IMMUNITY: SIGNIFICANCE OF ELEVATED LEVELS OF COMPLEMENT IN TUMOR BEARING HOSTS * , 1976, Annals of the New York Academy of Sciences.

[46]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[47]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[48]  A. Simon,et al.  Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. , 2003, The New England journal of medicine.

[49]  J. Gmiński,et al.  Immunoglobulins and complement components levels in patients with lung cancer. , 1992, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.